Exchange: NASDAQ·Updated 07:30 PM EDT

AUTL News

News
all
press releases
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
More News
Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees
Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees...
Yahoo! Finance: News
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Zacks
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
HC Wainwright Has Negative Outlook for AUTL Q2 Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company wil...
MarketBeat
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...
MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround
Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...
MarketBeat

Advertisement|Remove ads.